Specialty pharmaceutical company Supernus Pharmaceuticals has announced the launch of Oxtellar XR tablets in the US.
Oxtellar XR, a once-daily extended release formulation of oxcarbazepine, is an antiepileptic drug (AED), which is available in 150 mg, 300 mg and 600 mg dosage strengths.
The drug is indicated for adjunctive therapy in the treatment of partial seizures in adults and in children 6 to 17 years of age.
Supernus said depending on weight, the recommended daily dose for children 6 to 17 years of age is 900 mg to 1800 mg and for adults is 1200 mg to 2400 mg.
Supernus president and CEO Jack Khattar said, "The commercial launch of Oxtellar XR marks the achievement of our vision of becoming a commercial organization marketing its own products in the CNS specialty pharma sector."
